Faculty Profiles - HONDA, Takashi

Papers - HONDA, Takashi

Division display 41 - 60 of about 274 ／ All the affair displays >>

Risk factors for decreased bone mineral density in patients with metabolic dysfunction-associated steatotic liver disease: a cross-sectional study at a health examination center Reviewed International journal

Yokoyama S, Honda T, Ishizu Y, Imai N, Ito T, Yamamoto K, Mizuno K, Kojima T, Kariya N, Nakamura N, Kawashima H

Clinical Nutrition Vol. 43 ( 6 ) page： 1425 - 1432 2024.6

Outcomes of immune checkpoint inhibitor-induced liver toxicity managed by hepatologists in a multidisciplinary toxicity team Reviewed International journal

Ito T, Mizuno K, Yamamoto T, Yasuda T, Yokoyama S, Yamamoto K, Imai N, Ishizu Y, Honda T, Hama M, Kataoka T, Shimokata T, Ando Y, Kawashima H.

Hepatol Res. 2024.4

Intestinal Microbiome Associated with Efficacy of Atezolizumab and Bevacizumab Therapy for Hepatocellular Carcinoma Reviewed International journal Open Access

Inukai Y, Yamamoto K, Honda T*, Yokoyama S, Ito T, Ishigami M, Kawashima H

Cancers Vol. 26 ( 16 ) page： 1675 2024.4

Identification of the microbiome associated with prognosis in patients with chronic liver disease Reviewed International journal Open Access

Yamamoto K, Honda T, Inukai Y, Yokoyama S, Ito T, Imai N, Ishizu Y, Nakamura M, Kawashima H

Microorganisms Vol. 12 ( 3 ) page： 610 2024.3

Characteristics of microbiomes of the saliva, duodenal bulb, and descending portion of superficial nonampullary duodenal epithelial tumors Reviewed International journal

Shibata H, Yamamoto K, Hirose T, Furune S, Kakushima N, Furukawa K, Nakamura M, Honda T*, Fujishiro M, Kawashima H.

Dig Liver Dis 2024.2

Analysis of Neuropeptides in the Intestinal Mucus of Patients with Ulcerative Colitis Using RNA Sequencing Reviewed International journal

Nakamura M, Murate K, Maeda K, Yamamura T, Sawada T, Ishikawa E, Furukawa K, Hirose T, Uetsuki K, Iida T, Mizutani Y, Yamao K, Ishizu Y, Ishikawa T, Honda T, Kawashima H

Digestion Vol. 105 ( 5 ) page： 400 - 410 2024

Long-term monitoring and clinical implications of small bowel capsule endoscopy in patients with Crohn's disease with small bowel lesions: A Retrospective Analysis Reviewed International journal

Nakamura M, Yamamura T, Maeda K, Sawada T, Ishikawa E, Murate K, Furukawa K, Hirose T, Uetsuki K, Iida T, Mizutani Y, Yamao K, Ishizu Y, Ishikawa T, Honda T, Kawashima H

Digestion Vol. 105 ( 5 ) page： 380 - 388 2024

*Effects of 1‐kestose on microbiome changes caused by vonoprazan: a randomized, double‐blind, placebo‐controlled pilot study Reviewed International journal

Furune S, Suzuki T, Honda T*, Yamamoto K, Furukawa K, Nakamura M, Ishigami M, Kinoshita F, Kadota Y, Tochio T, Shimomura Y, Hirooka Y, Fujishiro M, Hirroka Y, Kawashima H

J Gastroenterol Hepatol. 2023.12

Monoclonal Antibody Against Mature Interleukin-18 Ameliorates Colitis in Mice and Improves Epithelial Barrier Function Reviewed International journal

Ikegami S, Maeda K, Urano T, Mu J, Nakamura M, Yamamura T, Sawada T, Ishikawa E, Yamamoto K, Muto H, Oishi A, Iida T, Mizutani Y, Ishikawa T, Kakushima N, Furukawa K, Ohno E, Honda T, Ishigami M, Kawashima H.

Inflamm Bowel Dis 2023.12

*Impact of elobixibat on liver tumors, microbiome, and bile acid levels in a mouse model of nonalcoholic steatohepatitis. Reviewed International journal

Sugiyama Y, Yamamoto K, Honda T*, Kato A, Muto H, Yokoyama S, Ito T, Imai N, Ishizu Y, Nakamura M, Asano T, Enomoto A, Zaitsu K, Ishigami M, Fujishiro M, Kawashima H

Hepatology international Vol. 17 ( 6 ) page： 1378 - 1392 2023.12

A new criterion including the aspartate aminotransferase-to-platelet ratio index and liver and spleen stiffness to rule out varices needing treatment in children with biliary atresia: Modification of the Baveno VII criteria. Reviewed International journal Open Access

Hepatology research : the official journal of the Japan Society of Hepatology 2023.10

Clinical course and prognosis of patients with hepatocellular carcinoma and haemophilia. Reviewed International journal Open Access

European journal of gastroenterology & hepatology Vol. 35 ( 10 ) page： 1211 - 1215 2023.10

Real-World Effectiveness and Risk Factors for Discontinuation of Ustekinumab in Ulcerative Colitis. Reviewed International journal

Inflammatory intestinal diseases Vol. 8 ( 2 ) page： 60 - 68 2023.10

Clinical characteristics of Dieulafoy’s Lesion in the Small Bowel Diagnosed and Treated by Double-Balloon Endoscopy Reviewed International journal Open Access

Nakamura M, Yamamura T, Maeda K, Sawada T, Ishikawa E, Furukawa K, Iida T, Mizutani Y, Yamao K, Ishikawa T, Honda T, Ishigami M, Kawashima H.

BMC Gastroenterol. Vol. 23 ( 1 ) page： 290 2023.8

Letter: 1-kestose, the smallest fructooligosaccharide component, protection for mild to moderate ulcerative colitis patients-authors' reply. Reviewed International journal Open Access

Alimentary pharmacology & therapeutics Vol. 57 ( 11 ) page： 1351 - 1352 2023.6

Abdominal pain accompanied by elevated serum inflammatory markers and biliary enzymes for diagnosing immune checkpoint inhibitor-induced sclerosing cholangitis. Reviewed International journal Open Access

Takafumi Yamamoto, Kazuyuki Mizuno, Takanori Ito, Shinya Yokoyama, Kenta Yamamoto, Norihiro Imai, Yoji Ishizu, Takashi Honda, Takuya Ishikawa, Akira Kanamori, Satoshi Yasuda, Hidenori Toyoda, Kenji Yokota, Tetsunari Hase, Naoki Nishio, Osamu Maeda, Makoto Ishii, Michihiko Sone, Yuichi Ando, Masashi Akiyama, Masatoshi Ishigami, Hiroki Kawashima

Investigational new drugs Vol. 41 ( 3 ) page： 512 - 521 2023.6

Language：English Publishing type：Research paper (scientific journal)

Immune-related sclerosing cholangitis (irSC) is relatively rare and its clinical characteristics are not well known. In this study, we aimed to summarize the clinical features of irSC. Clinical data were collected retrospectively from 1,393 patients with advanced malignancy treated with immune-checkpoint inhibitors (ICIs) between August 2014 and October 2021. We analyzed patients with immune-related adverse events of liver injury (liver-irAEs) and compared irSC and non-irSC groups. Sixty-seven patients (4.8%) had a liver-irAE (≥ grade 3) during the follow-up period (median, 262 days). Among these, irSC was observed in eight patients (11.9%). All patients in the irSC group were treated with anti-PD-1/PD-L1 antibodies. Compared with the non-irSC group, the irSC group showed mainly non-hepatocellular liver injury (87.5 % vs 50.8 %, P = 0.065), and had elevated serum inflammatory markers (e.g., CRP and NLR) and biliary enzymes (e.g., GGTP and ALP) at the onset of liver-irAEs. Furthermore, most patients with irSC had abdominal pain. In the non-irSC group, the liver injury of 23 patients improved only with the discontinuation of ICIs, and 22 patients improved with medication including prednisolone (PSL). Conversely, almost all patients (n=7) in the irSC group were treated with PSL, but only two patients experienced an improvement in liver injury. We found that irSC is characterized by a non-hepatocellular type of liver injury with abdominal pain and a high inflammatory response and is refractory to treatment. Further examination by imaging is recommended to detect intractable irSC in cases with these characteristics.

DOI： 10.1007/s10637-023-01366-3

Open Access

Scopus

PubMed

Pretreatment Proteinuria Predicts the Prognosis of Patients Receiving Systemic Therapy for Unresectable Hepatocellular Carcinoma. Reviewed International journal Open Access

Mizuno K, Imai N, Yamamoto T, Yokoyama S, Yamamoto K, Ito T, Ishizu Y, Honda T, Kuzuya T, Ishigami M, Kawashima H

Cancers Vol. 15 ( 10 ) 2023.5

Successful Treatment with Steroids in a Patient with Vanishing Bile Duct Syndrome and Acute Tubular Necrosis Reviewed International journal Open Access

Mizuno Fumitaka, Imai Norihiro, Yasuda Kazushi, Yokoyama Shinya, Yamamoto Kenta, Ito Takanori, Ishizu Yoji, Honda Takashi, Ishigami Masatoshi, Kawashima Hiroki

Internal Medicine Vol. advpub ( 0 ) 2023.5

Language：English Publishing type：Research paper (scientific journal) Publisher：The Japanese Society of Internal Medicine

<p>Vanishing bile duct syndrome (VBDS) is a rare but potentially serious cholestatic liver disease caused by various etiologies, including drugs. We herein report a complicated case of VBDS with acute tubular necrosis (ATN) that improved significantly with steroid treatment. An Asian man in his 30s was admitted with the acute onset of severe jaundice and a decline in the renal function. Although initial treatment with ursodeoxycholic acid did not reduce jaundice or renal dysfunction, steroid treatment remarkably improved the VBDS and ATN to within the respective normal ranges. Steroid treatment can be considered in cases of VBDS that appear to have an immune-mediated cause. </p>

DOI： 10.2169/internalmedicine.1826-23

Open Access

PubMed

CiNii Research

Distinct features of two lipid droplets types in cell nuclei from patients with liver diseases. Reviewed International journal Open Access

Imai N, Ohsaki Y, Cheng J, Zhang J, Mizuno F, Tanaka T, Yokoyama S, Yamamoto K, Ito T, Ishizu Y, Honda T, Ishigami M, Wake H, Kawashima H

Scientific reports Vol. 13 ( 1 ) page： 6851 2023.4

*Proteomic Analysis Reveals Changes in Tight Junctions in the Small Intestinal Epithelium of Mice Fed a High-Fat Diet Invited Reviewed International journal Open Access

Muto H, Honda T, Tanaka T, Yokoyama S, Yamamoto K, Ito T, Imai N, Ishizu Y, Maeda K, Ishikawa T, Adachi S, Chikara Sato C, Tsuji M N, Fujishiro M, Kawashima H

Nutrients Vol. 15 ( 1473 ) 2023.3

　 PREV - NEXT 　

<HONDA, Takashi>

Papers - HONDA, Takashi